These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be ...

Amgen acquired CD19-directed antibody Uplizna (inebilizumab ... a significant improvement in myasthenia gravis activities of daily living (MG-ADL) disease scores at 26 weeks compared to placebo ...

Amgen is preparing to file a third indication for Uplizna, as a twice-yearly therapy for generalised myasthenia gravis, following new phase 3 data.

Amgen is also advancing Uplizna for generalized myasthenia gravis, for which the FDA has granted it Orphan Drug Designation. A regulatory filing in this indication is planned for the first half of ...

highlighting the Company's innovative autoantibody disease research and the potential of nipocalimab to provide long-term sustained disease control in the treatment of generalized myasthenia ...

The Phase III MITIGATE trial demonstrated that Uplizna (inebilizumab) significantly reduces the risk of flares, lowers glucocorticoid dependence, and increases rates of treatment- and ...

Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to ...

Graviss Hospitality Ltd., incorporated in the year 1959, is a Small Cap company (having a market cap of Rs 282.92 Crore) operating in Tourism & Hospitality sector. Graviss Hospitality Ltd. key ...